Cesium Chloride For Use In Cancer Treatment

What is cesium chloride, you may well ask? It is a solid colorless compound created by combining cesium hydroxide and hydrochloric acid, which forms a salt. This salt is then purified via means of a recrystallization process, after which it is ready for use in a number of different ways as an important source of cesium ions.

Cesium is used in the high PH treatment of cancer and has proved successful in laboratory testing on mice to noticeably shrink cancerous tumors within as short a time as two weeks. Cesium chloride is easily absorbed by the cancerous cells, altering the PH balance within the cell to the 8+ range, where the life of the cell is significantly shortened and mitosis ceases. More exciting, all pains and symptoms associated with cancer were shown to cease within a 12 to 36 hour period after therapy was started.

The uptake of cesium chloride benefited from the addition of such vitamins as A and C and the addition of minerals like Zinc and Selenium. Patients who had undergone extended periods of treatment with chemotherapy and morphine for pain management were found to have longer recovery times in response to PH therapy.

The level of cesium chloride in the body becomes toxic at 135 grams. Ideally, the recommended dose is 6 grams a day to avoid any toxic effects. Cesium chloride is often mixed with rubidium, combining the rubidium ions with the cesium chloride ions to aid in upping the PH balance of the cells. The vitamins and mineral salts work together as strong electron donors and aid in the break down of the cancerous cells in the body.

Noted side effects of the treatment were nausea and diarrhea, both of which can be treated easily enough. Administering the cesium chloride in a mixture of sorbitol negated the effects of nausea and the addition of vitamin C somewhat negated the effects of the diorrhea. Patients who have undergone the treatment have noted almost miraculous results by the shrinkage and disappearance of their tumors.

About the Author:

Comments are closed.